MIST
Milestone Pharmaceuticals Inc. · Healthcare
Insiders sold $158K of Milestone Pharmaceuticals Inc. in the last 12 months and bought none
MIST over the last year
MIST after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2019 with 3 months of prices.
Every filing
16 insider filings since 2019, newest first
David Bharucha · Chief Medical Officer
David Bharucha · Chief Medical Officer
Rtw Investments, LP · 10% owner
Paul F Truex · Director
Fonds De Solidarite Des Travailleurs Du Quebec · 10% owner
Rtw Investments, LP · 10% owner
Rtw Investments, LP · 10% owner
Rtw Investments, LP · 10% owner
Rtw Investments, LP · 10% owner
Novo Holdings A/s · 10% owner
Rtw Investments, LP · 10% owner
Rtw Investments, LP · 10% owner
Fonds De Solidarite Des Travailleurs Du Quebec · 10% owner
Novo Holdings A/s · 10% owner
Rtw Investments, LP · 10% owner
Bdc Capital Inc. · 10% owner
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.